You can get some good investment ideas by keeping an eye on big investors.
Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.
The better burger shop's stock might not be done falling through the floor just yet.
These companies may be technically separated nowadays, but they still go together like milk and cookies.
Critics have no shortage of concerns with Obamacare, but they might be shocked by this unexpected benefit.
The marijuana industry is facing a long list of obstacles, but this major one has flown under the radar of consumers and investors until recently.
Cheer for a potential cure and not for the ensuing profits (or lack thereof).
These five drugs will set insurers and patients back anywhere from $375,000 per year to as much as $1.21 million per year.
Marijuana could play a critical role in determining who becomes the next president of the United States. Based on previous commentary, these three candidates might be the most marijuana-friendly of the field.
Celgene trounced Wall Street's expectations in the second quarter, but it's these five things that its management team most wants you to know.